The FY26 ALS Research Program Pilot Clinical Trial Award funds phase 1 to small-scale phase 2 clinical trials aimed at impactful treatments or clinical care improvements for ALS. Projects must incorporate mechanism-specific biomarkers for therapeutic interventions, community collaboration, detailed regulatory strategies, and transition plans to advance study outcomes. Trials should start within 12 months or 18 months for FDA-regulated studies.
Open to any type of entity without restrictions, subject to additional clarifications in eligibility text. No specific career stage or organization type limitations stated.
